询 单
请 填 写 相 关 信 息
产品信息
产品名称
别名
CAS号
结构式 上传
联系方式
公司
联系人
电话
邮箱
内容
提交
中文版 English
请输入产品名称、CAS式、分子式
2,4-Dihydro-4-(4-methylphenyl)-3H-1,2,4-triazol-3-one | CAS:93192-57-5
2,4-Dihydro-4-(4-methylphenyl)-3H-1,2,4-triazol-3-one
  • 名称:2,4-二氢-4-(4-甲基苯基)-3H-1,2,4-三唑-3-酮 | 2,4-Dihydro-4-(4-methylphenyl)-3H-1,2,4-triazol-3-one
  • CAS号:93192-57-5
  • 别名:
  • 分子式:C9H9N3O
  • 分子量:175.19
  • EINESC号:

产品描述

物理化学性质

密度 1.27±0.1 g/cm3 (20 ºC

安全数据

没有数据没有数据

SDS

来源 SDS样本
没有数据没有数据
产品合成路线
更多

名称 CAS号
更多
文章
同行评议文献
Comparative study on the effects of some polyoxyethylene alkyl ether and sorbitan fatty acid ester surfactants on the performance of transdermal carvedilol proniosomal gel using experimental design.Ahmed A Aboelwafa et al.AAPS PharmSciTech, 11(4), 1591-1602 (2010-11-11) An investigation into the role of surfactants in controlling particle size of polymeric nanocapsules containing penicillin-G in double emulsion.Sepideh Khoee et al.European journal of medicinal chemistry, 44(6), 2392-2399 (2008-11-18) Surfactant-stabilized microbubbles as ultrasound contrast agents: stability study of [TM="Span"] 60 and Tween 80 mixtures using a Langmuir troughSinghal, S., et al. Langmuir, 9, 2426-2426 (1993) Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid.Varaporn Buraphacheep Junyaprasert et al.International journal of pharmaceutics, 423(2), 303-311 (2011-12-14) Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation.Amit Rawat et al.Journal of controlled release : official journal of the Controlled Release Society, 128(3), 224-232 (2008-05-13) Preparation and characterization of molecularly imprinted microspheres for dibutyl phthalate recognition in aqueous environment.Juan He et al.Journal of separation science, 33(21), 3409-3414 (2010-10-12) Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design.Ajay B Solanki et al.AAPS PharmSciTech, 8(4), E86-E86 (2008-01-10) Low molecular weight heparin loaded pH-sensitive microparticles.Yvette Meissner et al.International journal of pharmaceutics, 335(1-2), 147-153 (2006-12-08) Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicine.Aline Ferreira Ourique et al.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 79(1), 95-101 (2011-03-16) Spanlastics--a novel nanovesicular carrier system for ocular delivery.Shilpa Kakkar et al.International journal of pharmaceutics, 413(1-2), 202-210 (2011-05-05) Fatty alcohols or fatty acids as niosomal hybrid carrier: effect on vesicle size, encapsulation efficiency and in vitro dye release.Prasun Bandyopadhyay et al.Colloids and surfaces. B, Biointerfaces, 58(1), 68-71 (2007-03-07) Preparation and characterization of niosomes containing ribavirin for liver targeting.Fahima Hashim et al.Drug delivery, 17(5), 282-287 (2010-03-31) Air-jet and vibrating-mesh nebulization of niosomes generated using a particulate-based proniosome technology.Abdelbary Elhissi et al.International journal of pharmaceutics, 444(1-2), 193-199 (2013-01-10) Novel ultrasound contrast agent based on microbubbles generated from surfactant mixtures of Span 60 and polyoxyethylene 40 stearate.Zhanwen Xing et al.Acta biomaterialia, 6(9), 3542-3549 (2010-03-17) Effect of sorbitan monostearate on the physical characteristics and whipping properties of whipped cream.Qiangzhong Zhao et al.Food chemistry, 141(3), 1834-1840 (2013-07-23) Effects of surfactant characteristics on drug availability from suppositories.N Realdon et al.Die Pharmazie, 63(6), 459-463 (2008-07-09) Caffeine-loaded niosomes: characterization and in vitro release studies.Payam Khazaeli et al.Drug delivery, 14(7), 447-452 (2007-11-13) Evidence for vesicle formation from 1:1 nonionic surfactant span 60 and fatty alcohol mixtures in aqueous ethanol: potential delivery vehicle composition.Prasun Bandyopadhyay et al.Colloids and surfaces. B, Biointerfaces, 58(2), 305-308 (2007-04-07) Design and optimization of surfactant-based nanovesicles for ocular delivery of Clotrimazole.Mona Basha et al.Journal of liposome research, 23(3), 203-210 (2013-04-24) Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.Ismail A Attia et al.AAPS PharmSciTech, 8(4), E106-E106 (2008-01-10) Evaluation of the physical stability of two oleogels.Isabel F Almeida et al.International journal of pharmaceutics, 327(1-2), 73-77 (2006-09-26) In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration.Mohamed Nasr AAPS PharmSciTech, 11(1), 85-89 (2010-01-09) Preparation of curcuminoid niosomes for enhancement of skin permeation.N Rungphanichkul et al.Die Pharmazie, 66(8), 570-575 (2011-09-10) Stability of luciferase plasmid entrapped in cationic bilayer vesicles.A Manosroi et al.International journal of pharmaceutics, 356(1-2), 291-299 (2008-02-19) Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse.I F Uchegbu et al.Pharmaceutical research, 12(7), 1019-1024 (1995-07-01) The preparation of pellets containing non-ionic surfactants by extrusion/spheronization.F Podczeck et al.International journal of pharmaceutics, 361(1-2), 33-40 (2008-06-24) Preparation and properties of vesicles (niosomes) of sorbitan monoesters ([TM="Span"] 20, 40, 60 and 80) and a sorbitan triester ([TM="Span"] 85).Yoshioka, T., et al. International Journal of Pharmaceutics, 105, 1-1 (1994) Studies on nonionic surfactant bilayer vesicles of ciclopirox olamine.Karimunnisa Sameer Shaikh et al.Drug development and industrial pharmacy, 36(8), 946-953 (2010-03-04) Moisturizing effect of oleogel/hydrogel mixtures.I F Almeida et al.Pharmaceutical development and technology, 13(6), 487-494 (2008-08-23) [9-nitrocamptothecin nanostructured lipid carrier system: in vitro releasing characteristics, uptake by cells, and tissue distribution in vivo].Jun-chan Li et al.Yao xue xue bao = Acta pharmaceutica Sinica, 40(11), 970-975 (2006-02-28)
备注

Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).

名称 CAS号

相关产品

相关资讯

热门标签
询 单
请 填 写 相 关 信 息
产品信息
产品名称
别名
CAS号
结构式 上传
联系方式
公司
联系人
电话
邮箱
内容
提交